Rescue therapy after Helicobacter pylori eradication failure

被引:15
作者
Gisbert, Javier P. [1 ]
机构
[1] Hosp Univ La Princesa, Serv Aparato Digest, Madrid, Spain
来源
GASTROENTEROLOGIA Y HEPATOLOGIA | 2011年 / 34卷 / 02期
关键词
Helicobacter pylori; Rescue; Failure; Metronidazole; Clarithromycin; Levofloxacin; Rifabutin; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; DOSE DUAL THERAPY; QUADRUPLE THERAPY; TRIPLE THERAPY; 2ND-LINE TREATMENT; AMOXICILLIN-METRONIDAZOLE; JAPANESE POPULATION; INFECTED PATIENTS; RANDOMIZED-TRIAL;
D O I
10.1016/j.gastrohep.2010.10.013
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Despite the use of currently-recommended therapies, at least 20% of patients remain infected after a first attempt at Helicobacter pylori eradication. Therefore, when designing a therapeutic strategy, rather than focus exclusively on the result of the first eradication therapy, from the outset physicians should plan the sequence of consecutively administered combinations with the highest possibility of achieving a 100% success rate. The choice of rescue therapy depends on the drugs used in the first eradication attempt, since repeating the same antibiotic is not recommended. Systematic bacterial culture after a first H. pylori eradication failure does not seem to be required in clinical practice and this technique can be reserved for patients with a second failed attempt. There are several possibilities for empirical rescue therapy (without knowing the bacterial sensitivity). After failure of the combination of a proton pump inhibitor (PPI), amoxicillin and clarithromycin the most widely used combination in Spain, quadruple therapy (PPI-bismuth-tetracycline-metronidazole) has been the most widely used treatment. More recently, levofloxacin (together with amoxicillin and a PPI) is as effective as quadruple therapy, or more so, and has the advantage of being simpler and better tolerated. In addition, rescue therapy with levofloxacin is a promising third-line alternative after failure of two eradication therapies containing key antibiotics such as amoxicillin, clarithromycin, metronidazole and tetracycline. Finally, rifabutin-based therapies have achieved promising results and are even effective in patients with multiple failures or multiple antibiotic resistance. (C) 2010 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:89 / 99
页数:11
相关论文
共 53 条
[1]   In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657 [J].
Akada, JK ;
Shirai, M ;
Fujii, K ;
Okita, K ;
Nakazawa, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1072-1076
[2]  
Avidan B, 2001, ISRAEL MED ASSOC J, V3, P163
[3]   Treatment of Helicobacter pylori:: an overview [J].
Axon, ATR .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 :1-6
[4]   Efficacy of Helicobacter pylori eradication therapies: A single centre observational study [J].
Beales I.L.P. .
BMC Gastroenterology, 1 (1)
[5]   RIFABUTIN - A REVIEW OF ITS ANTIMICROBIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY [J].
BROGDEN, RN ;
FITTON, A .
DRUGS, 1994, 47 (06) :983-1009
[6]   Nitrofuran-based regimens for the eradication of Helicobacter pylori infection [J].
Buzas, Gyoergy M. ;
Jozan, Jolan .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (10) :1571-1581
[7]   Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori [J].
Chi, CH ;
Lin, CY ;
Sheu, BS ;
Yang, HB ;
Huang, AH ;
Wu, JJ .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (03) :347-353
[8]  
Choung Rok Son, 2006, Korean J Gastroenterol, V47, P131
[9]  
Cudia B, 1997, GUT, V41, pA103
[10]  
DEBOER WA, 1994, AM J GASTROENTEROL, V89, P1993